TABLE 2.
The characteristics of the patients in the index and reference groups.
| Without PI | With PI | |||
|---|---|---|---|---|
| Without FXaI n = 55,599 | With FXaI n = 82,643 | Without FXaI n = 20,721 | With FXaI n = 354 | |
| Patient gender | ||||
| Female | 24,975 (44.9%) | 41,258 (49.9%) | 8,991 (43.4%) | 149 (42.1%) |
| Male | 30,624 (55.1%) | 41,385 (50.1%) | 11,730 (56.6%) | 205 (57.9%) |
| Median age, years (SD) | 70 (10.9) | 73 (13.7) | 67 (11.3) | 73 (9.6) |
| Patient age group (years) | ||||
| 18–34 | 121 (0.2%) | 1,542 (1.9%) | 180 (0.9%) | 0 (0%) |
| 35–64 | 17,438 (31.4%) | 19,428 (23.5%) | 8,282 (40.0%) | 66 (18.6%) |
| 65–74 | 19,357 (34.8%) | 22,870 (27.7%) | 7,334 (35.4%) | 148 (41.8%) |
| >75 | 18,683 (33.6%) | 38,803 (47.0%) | 4,925 (23.8%) | 140 (39.5%) |
| Severity | ||||
| Initial or prolonged hospitalization | 21,458 (38.6%) | 46,332 (56.1%) | 9,174 (44.3%) | 199 (56.2%) |
| Disability | 1,049 (1.9%) | 2,065 (2.5%) | 489 (2.4%) | 8 (2.3%) |
| Life-threatening | 2,002 (3.6%) | 5,018 (6.1%) | 1,227 (5.9%) | 27 (7.6%) |
| Death | 15,607 (28.1%) | 13,064 (15.8%) | 3,944 (19.0%) | 44 (12.4%) |
FXaI, factor xa inhibitors; PI, proteasome inhibitors; SD, Standard Deviation.